Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
RETAIN
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
- NCT02710734 ↗
- Completed
- Fox Chase Cancer Center
- Focused
We haven't built an HCP commentary report on RETAIN yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RETAIN so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Urothelial Carcinoma of the Bladder
- Interventions
- Methotrexate; Vinblastine; Doxorubicin; Cisplatin; Intensity modulated radiation therapy (IMRT); Transurethral Resection of Bladder tumor; 5-FU; Mitomycin C
- Arms
- CRT · Experimental
- Surveillance · Experimental
- Intravesicle therapy · Experimental
- Radical Cystectomy · Experimental
- Enrollment
- 78
- Primary outcomes
- Metastasis-free survival (MFS) at 2 years.
- Sponsor
- Fox Chase Cancer Center
- Start
- Feb 24, 2016
- Primary completion
- Nov 27, 2025
- Results posted
- No
- Registry record
- NCT02710734 · updated May 22, 2026
Publications
linked from the registry- Geynisman DM, Abbosh PH, Ross E, Zibelman MR, Ghatalia P, Anari F, Mark JR, Stamatakis L, Hoffman-Censits JH, Viterbo R, Greenberg RE, Churilla TM, Horwitz EM, Hallman MA, Smaldone MC, Uzzo R, Chen DYT, Kutikov A, Plimack ER. Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). J Clin Oncol. 2025 Mar 20;43(9):1113-1122. doi: 10.1200/JCO-24-01214. Epub 2024 Dec 16. PubMed 39680823
- Jiang DM, Chung P, Kulkarni GS, James ND, Sridhar SS. Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer : In response to: Dirk Bohmer and Arne Grun. Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer. Curr Oncol Rep. 2021 Mar 3;23(3):36. doi: 10.1007/s11912-021-01035-9. No abstract available. PubMed 33660142